Egyptian scientist Nabil Seidah wins the 2025 Great Arab Minds Award in Medicine for groundbreaking heart-health research.

Egyptian scientist Dr Nabil Seidah has won the 2025 Great Arab Minds Award for Medicine in recognition of his contributions ...

Sheikh Mohammed bin Rashid Al Maktoum highlights Dr. Nabil Seidah's scientific contributions to understanding cholesterol ...

On December 11, 2025- Kowa Company, Ltd. initiated a phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With ...

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients' treatment significantly reduced the risk of major ...

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk. By Gina Kolata Merck, the company that introduced statins to the ...

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the arteries and cardiovascular health. Now, a study led by the University of ...

Enlicitide demonstrated statistically significant and clinically meaningful reductions in LDL-C in both Phase 3 CORALreef HeFH and CORALreef AddOn trials Enlicitide, a novel macrocyclic peptide, has ...